David T. Curiel, M.D., Ph.D.
Director, Division of Cancer Biology
Director, Biologic Therapeutics Center
 
 

Research

The focus of my research program is to exploit adenoviral agents for applications to the applied contexts of cancer therapeutics.  These efforts embody basic molecular virology to modify adenoviral tropism towards the goal of targeted delivery.  In addition, studies to employ adenovirus as virotherapy agents embody studies of basic cancer biology to adapt the virus tumor selective in its replicative capacity.  Both of these programs also include the development of imaging modalities for disease detection and monitoring of therapy outcomes. Our program includes a strong bench-to-bed ethos with translation of promising strategies to the context of human clinical trials.

Biography:  

David T. Curiel, M.D., Ph.D. is the Director of the Cancer Biology Division of the Department of Radiation Oncology at Washington University School of Medicine.  Dr. Curiel graduated medical school at Emory University in 1982, where he also completed his internship and residency in Internal Medicine.  Dr. Curiel’s scientific training includes tenureship at the National Institutes of Health in Bethesda, Maryland at the Pulmonary Branch of the Heart and Lung, and Blood Institute (NHLBI) from 1985-1989, and a fellowship in Biotechnology at the National Cancer Institute, Navy Medical Oncology Branch from 1989-1990.  He received his Ph.D. from University of Groningen in The Netherlands in 2002.  Dr. Curiel has been at Washington University School of Medicine since 2011.  In addition to his role as Director of the Cancer Biology Division, he is Director of the Biologic Therapeutics Center.

Publications

  1. Potent Antitumor Immunity Generated by a CD40-Targeted Adenoviral Vaccine. Hangalapura BN, Oosterhoff D, de Groot J, Boon L, Tüting T, van den Eertwegh AJ, Gerritsen WR, van Beusechem VW, Pereboev A, Curiel DT, Scheper RJ, de Gruijl TD. Cancer Res. 2011 Sep 1;71(17):5827-37. Epub 2011 Jul 11.
  2. Genetic incorporation of human metallothionein into the adenovirus protein IX for non-invasive SPECT imaging. Mathis JM, Bhatia S, Khandelwal A, Kovesdi I, Lokitz SJ, Odaka Y, Takalkar AM, Terry T, Curiel DT. PLoS One. 2011 Feb 9;6(2):e16792.
  3. A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases. Kimball KJ, Preuss MA, Barnes MN, Wang M, Siegal GP, Wan W, Kuo H, Saddekni S, Stockard CR, Grizzle WE, Harris RD, Aurigemma R, Curiel DT, Alvarez RD. Clin Cancer Res. 2010 Nov 1;16(21):5277-87.
  4. Derivation of a triple mosaic adenovirus for cancer gene therapy.  PLoS One.Tang Y, Wu H, Ugai H, Matthews QL and Curiel DT (2010). 2009 Dec 31;4(12):e8526.
  5. A strategy for adenovirus vector targeting with a secreted single chain antibody. Glasgow JN, Mikheeva G, Krasnykh V and Curiel DT (2010). PLoS One. 2009 Dec 21;4(12):e8355.
  6. In vitro dynamic visualization analysis of fluorescently labeled minor capsid protein IX and core protein V by simultaneous detection. Ugai H, Wang M, Le LP, Matthews DA, Yamamoto M and Curiel DT (2009). J Mol Biol. 395:55-78.
  7. A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo. Thacker EE, Nakayama M, Smith BF, Bird RC, Muminova Z, Strong TV, Timares L, Korokhov N, O'Neill AM, de Gruijl TD, Glasgow JN, Tani K and Curiel DT (2009). Vaccine. 27:7116-7124.
  8. Chimeric adenoviral vectors incorporating a fiber of human adenovirus 3 efficiently mediate gene transfer into prostate cancer cells. Murakami M, Ugai H, Belousova N, Pereboev A, Dent P, Fisher PB, Everts M, and Curiel DT (2009). Prostate. 70:362-376.
  9. Development of an optimized conditionally replicative adenoviral agent for ovarian cancer. Zhu ZB, Lu B, Park M, Makhija SK, Numnum TM, Kendrick JE, Wang M, Tsuruta Y, Fisher P, Alvarez RD, Zhou F, Siegal GP, Wu H and Curiel DT (2008).   Int J Oncol. 32:1179-1188.
  10. A fiber-modified mesothelin promoter-based conditionally replicating adenovirus for treatment of ovarian cancer. Tsuruta Y, Pereboeva L, Breidenbach M, Rein DT, Wang M, Alvarez RD, Siegal GP, Dent P, Fisher PB and Curiel DT (2008). Clin Cancer Res. 14:3582-3588.
  11. Optimization of capsid-incorporated antigens for a novel adenovirus vaccine approach.  Matthews QL, Yang P, Wu Q, Belousova N, Rivera AA, Stoff-Khalili MA, Waehler R, Hsu HC, Li Z, Li J, Mountz JD, Wu H and Curiel DT (2008).  Virol J. 5:98.

 

David T. Curiel, M.D., Ph.D.
 

Address

4511 Forest Park Ave

Campus Box

8224

City/St/Zip

St. Louis, MO 63108

Office

 

Phone

(314) 747-5443

Fax

(314) 362-9790

Email

dcuriel@radonc.wustl.edu

Education

  • B.A. Chemistry, West Georgia College, 1974–1978 Carrollton, Georgia, Summa cum laude
  • M.D.  Emory University School of Medicine, 1978-1982
    Atlanta, Georgia
  • Internship – Medicine,  Emory University, 7/1982–7/1983   Affiliated Hospitals, Atlanta, Georgia
  • Residency – Medicine, Emory University 7/1983–7/1985 Affiliated Hospitals, Atlanta, Georgia
  • Ph.D. Groningen University, 12/2002 Groningen, Netherlands
 
Print this page | Close
spacer spacer spacer